Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | TGM1 | P22735 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006320 | 1.00 | NPY5R (0.62) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7014453 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7007035 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7010520 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7007042 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7006639 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL1983510 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7012950 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL1983511 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL7006631 | 0.96 | NPY5R (0.67) | NPY5RKMT2AMEN1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | NPY5R 4498/4885KMT2A 1952/4885MEN1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.